Evidence map›Paper›PMID 42489275›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Oral Delivery Systems for Food-Derived Bioactive Peptides: Enhancing Stability, Bioavailability, and Health Benefits.

Yu Xu, Fan Li, Runan Zhao, Tao Shu, Weihong Min, Bei-Wei Zhu

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu XuState Key Laboratory For Development and Utilization of Forest Food Resources, Zhejiang A&F University, Hangzhou, P. R. China.ORCID https://orcid.org/0009-0002-5861-4323
Fan LiState Key Laboratory For Development and Utilization of Forest Food Resources, Zhejiang A&F University, Hangzhou, P. R. China.ORCID https://orcid.org/0009-0004-6176-2698
Runan ZhaoCollege of Biosystems Engineering and Food Science, Fuli Institute of Food Science, Zhejiang University, Hangzhou, P. R. China.ORCID https://orcid.org/0000-0002-7581-5058
Tao ShuState Key Laboratory For Development and Utilization of Forest Food Resources, Zhejiang A&F University, Hangzhou, P. R. China.
Weihong MinState Key Laboratory For Development and Utilization of Forest Food Resources, Zhejiang A&F University, Hangzhou, P. R. China.
Bei-Wei ZhuSKL of Marine Food Processing and Safety Control, National Engineering Research Center of Seafood, Collaborative Innovation Center of Seafood Deep Processing, School of Food Science and Technology, Dalian Polytechnic University, Dalian, P. R. China.

Funding

National Natural Science Foundation of China 22408342Research Development Foundation of Zhejiang A&F University 2024LFR067
6 · The paper itself

Abstract

Food-derived bioactive peptides (FBPs) represent a promising class of nutraceuticals for the prevention and management of chronic diseases due to their diverse bioactivities and high biocompatibility; however, their therapeutic potential is severely limited by low oral bioavailability resulting from instability during processing, sensory drawbacks such as bitterness, and extensive gastrointestinal degradation. This review systematically outlines the major bottlenecks hindering the oral delivery of FBPs, including sensitivity to environmental factors (temperature, pH, metal ions) and physiological barriers (enzymatic hydrolysis, mucus layer, and epithelial transport). To overcome these challenges, advanced delivery systems, such as nanoparticles (NPs), nanoemulsions (NEs), liposomes, hydrogels, and composite carriers, have been designed. These engineered systems have demonstrated enhanced bioactivity and targeted delivery in preclinical models of neuroprotection, anti-inflammatory therapy, metabolic regulation, and cancer treatment, often outperforming free peptides in terms of stability and intestinal absorption. However, establishing quantitative correlations between formulation parameters and in vivo peptide bioavailability remains a critical bottleneck. Future research should focus on rationally designed stimuli-responsive platforms grounded in intestinal physiology, supported by standardized frameworks for scalable manufacturing and safety evaluation. This work provides a comprehensive framework for advancing FBPs delivery platforms toward functional food and chronic disease management applications.

Indexed as

Dietary SupplementsDrug Delivery SystemsPeptidesAdministration, OralAnimalsBioactive Peptides, DietaryBiological AvailabilityHumansBioactive Peptides, DietaryPeptidesbioavailabilitychronic diseasesdelivery systemsfood‐derived bioactive peptidesoral delivery

Identifiers

PMID42489275
PMCPMC13393286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.